-
公开(公告)号：US20220280417A1
公开(公告)日：2022-09-08
申请号：US17746647
申请日：2022-05-17
IPC分类号： A61K9/00 , A61K47/34 , A61K31/519
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
-
公开(公告)号：US20190117554A1
公开(公告)日：2019-04-25
申请号：US16220201
申请日：2018-12-14
IPC分类号： A61K9/00 , A61K47/34 , A61K31/519
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
-
公开(公告)号：US20180318208A1
公开(公告)日：2018-11-08
申请号：US16032270
申请日：2018-07-11
IPC分类号： A61K9/00 , A61K47/34 , A61K31/551 , A61K31/4468 , A61K31/4196 , A61K31/519
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/4196 , A61K31/4468 , A61K31/519 , A61K31/551 , A61K47/34
摘要： Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
-
公开(公告)号：US20180221272A1
公开(公告)日：2018-08-09
申请号：US15944894
申请日：2018-04-04
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/519 , A61K47/34
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
-
公开(公告)号：US07820202B2
公开(公告)日：2010-10-26
申请号：US10378733
申请日：2003-03-04
申请人： Roland Bodmeier
发明人： Roland Bodmeier
CPC分类号： A61K9/1694 , A61K9/1647
摘要： The invention relates to extended release compositions that can be advantageously used as drug products, plant protection agents, in foods or other products. The invention especially relates to liquid compositions in which extended release particles are dispersed. The compositions according to this invention are available in the form of single-dose or multi-dose compositions and as such are produced from liquid preproducts. The invention further relates to kits and methods for producing the compositions and to the preproducts thereof.
摘要翻译： 本发明涉及可有利地用作药物产品，植物保护剂，食品或其他产品的延长释放组合物。 本发明特别涉及其中分散有延长释放颗粒的液体组合物。 根据本发明的组合物可以单剂量或多剂量组合物的形式获得，因此由液体前产物制备。 本发明还涉及用于制备组合物及其前产物的试剂盒和方法。
-
公开(公告)号：US11752094B2
公开(公告)日：2023-09-12
申请号：US17746647
申请日：2022-05-17
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/519 , A61K47/34
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.
-
公开(公告)号：US11752092B2
公开(公告)日：2023-09-12
申请号：US17104337
申请日：2020-11-25
IPC分类号： A61K9/00 , A61K31/519 , A61K47/34 , A61K47/20
CPC分类号： A61K9/0002 , A61K9/0024 , A61K31/519 , A61K47/34 , A61K47/20
摘要： Injectable depot compositions comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.
-
8.发明申请公开(公告)号：US20230029399A1
公开(公告)日：2023-01-26
申请号：US17747422
申请日：2022-05-18
IPC分类号： A61K9/00 , A61K31/519 , A61K47/20 , A61K47/34 , A61P25/18
摘要： A method of treating an episode of acute exacerbation of schizophrenia by intramuscular administration of a long-acting injectable depot composition containing risperidone is provided. The method provides a substantial reduction in PANSS (both positive and negative scales) and CGI-S scores within about eight days after administration of the composition and for up to at least four weeks. The method is used to treat a subject suffering a first-time episode of or a relapse of severe to moderate symptoms associated with schizophrenia. The method does not require loading doses of risperidone in the depot composition and does not require supplementation with oral risperidone after administration of the depot composition.
-
公开(公告)号：US10933015B2
公开(公告)日：2021-03-02
申请号：US16294052
申请日：2019-03-06
IPC分类号： A61K9/00 , A61K31/4196 , A61K47/34
摘要： The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer.
-
公开(公告)号：US10182982B2
公开(公告)日：2019-01-22
申请号：US15944894
申请日：2018-04-04
IPC分类号： A61K9/00 , A61K47/34 , A61K31/519
摘要： The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.02 秒)
